Bio B2B 〉 Breaking News

Oncolys and Chugai reached a licensing agreement for Telomelysin (OBP-301)【2019.04.10】

Source : Taiwan Healthcare+
Published : 2019-04-10

Oncolys struck a deal with Chugai Pharmaceutical for the development, manufacture and marketing of the drug OBP-301 in Taiwan and Japan

Oncolys BioPharma Inc. and Chugai Pharmaceutical Co., Ltd. announced Monday the both companies have entered into an agreement that Oncolys will grant an exclusive license, with sublicensing rights, to Chugai concerning the development, manufacturing and marketing in Japan and Taiwan for “Telomelysin (OBP-301)” (hereafter, “Telomelysin”) an oncolytic viral immunotherapy which is currently under development by Oncolys. In addition, licensing agreement that grantsexclusive option rights concerning the worldwide development, manufacturing and marketing of Telomelysin, excluding Japan, Taiwan, China, Hong Kong and Macau to Chugai has also been concluded. Moreover, both companies agreed that Oncolys will newly issue common stock worth approximately 800 million yen, and Chugai will accept all the stocks. The start of this licensing agreement and the payment accompanying the issuance of new shares by third-party allotment are planned on April 24, 2019.
Drugmaker Medigen Biotechnology Corp yesterday said its Japanese partner Oncolys Biopharma Inc has reached licensing and capital tie-up agreements with a third party regarding the OBP-301 liver cancer medicine, which is expected to benefit the Taiwanese firm based on the terms of their partnership.
Medigen said in a regulatory filing that based on its strategic alliance and licensing agreement with Oncolys, the company could enjoy up to one-third of commercial interests of OBP-301 (Telomelysin).
As the licensing agreement is to take effect on April 24, Medigen would see a licensing contribution from the deal later this month and other milestone payments after that.
OBP-301 is a cancer treatment developed by Medigen and Oncolys over more than 10 years.
Chugai shall pay 550 million yen as an upfront payment for the exclusive licensing agreement, with sublicensing rights, in Japan and Taiwan. If a certain level of efficacy has been confirmed in the clinical study of Telomelysin, and in case Chugai exercised the exclusive option rights described above, the total value of the licensing agreement which Chugai shall pay to Oncolys will be 50 billion yen or more. In addition, after the launch of Telomelysin, Chugai shall pay to Oncolys, sales royalties according to Chugai's amount of sales of Telomelysin, apart from the total value of the licensing agreement.

About Telomelysin (OBP-301)
In preclinical studies for Telomelysin, Oncolys has demonstrated effective anti-tumor activity on various cancer cells, and there was no finding that may bring safety concerns in toxicological studies as well as bio-distribution study. Oncolys completed the phase 1 clinical trial for solid tumors in the US with 16 subjects for single dosing and 6 subjects for repeated dosing. Most of the adverse events observed in the study was mild to moderate and transient, and there was a sign of efficacy showing tumor shrinkage in 8 out of 12 evaluable patients.
In Japan, investigator initiated clinical research for esophageal cancer in combination with radiotherapy has been conducted in Okayama University. In cohort 1, 4 out of 7 patients (1 withdrawn due to the progress of other diseases) showed CR (complete response), and CD8 T cell infiltration was observed in tumor area. Based on positive results in this study, phase 1 study is ongoing.
In addition, Oncolys has been conducting phase 1 clinical trial of Telomelysin targeting hepatocellular carcinoma patients refractory to existing cancer treatments in Korea and Taiwan under the IND approved by the US FDA, which is collaboratively conducted with Taiwanese biotech company, called Medigen Biotechnology Corp. 17 patients in total (single dosing cohorts, 1 to 4; 3 patients in each cohort, multiple dosing cohort, 5; up to 6 patients) have been enrolled to date, and DSMB confirmed the safety of intrahepatically administered Telomelysin. We have a ongoing melanoma phase 2 study in the US. This study has enrolled 3 patients to date.

PharmaEngine partner gains European approval for PEP503 (NBTXR3) 【2019.04.08】

Source : Taipei Times
Published : 2019-04-08

Drug developer PharmaEngine Inc said its French partner Nanobiotix SA has received European market approval for PEP503 (NBTXR3), enabling commercialization of the nanoparticle radio-enhancer in the EU for the treatment of locally advanced soft-tissue sarcoma.

-Read More-

Novo Nordisk partners with Taiwan's Health2Sync to bring its diabetes management app to Japan【2019.03.12】

Source : Fierce Biotech
Published : 2019-03-12

Novo Nordisk has partnered with Taiwan-based Health2Sync to help promote the latter's digital diabetes management app in Japan...

-Read More-

PharmaEssentia and AOP Orphan Receive EU Approval of Besremi™ for Treatment of Polycythemia Vera (PV) in EU【2019.02.21】

Source : Taiwan Healthcare+
Published : 2019-02-21

PharmaEssentia today announced that the European Commission (EC) has approved Besremi® (ropeginterferon alfa-2b, P1101) as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly...

-Read More-

Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare【2019.02.11】

Source : Taiwan Healthcare+
Published : 2019-02-11

An exclusive license agreement for the commercialisation of Foresee Pharmaceutical's novel FP-001 program (leuprorelin depot), Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous depot formulations has been granted to Accord Healthcare....

-Read More-

TLC appoints George Spencer-Green as CMO【2019.02.05】

Source : BioSpectrumAsia
Published : 2019-02-05

With more than three decades of clinical medicine and drug development experience, Dr. Spencer-Green will serve as a member of the TLC Management Team and guide the company in its clinical and regulatory activities...

-Read More-

CellMax Life to Provide Blood Test for Medigen Biotech's Colorectal Cancer Cell Therapy Clinical Trials【2019.01.28】

Source : Taiwan Healthcare+
Published : 2019-01-28

Leading diagnostics company will offer ultra-sensitive tumor cell detection technology CMx TM to enable treatment selection and real- time monitoring of treatment response in patients with early stage cancer...

-Read More-

TaiwanJ Pharmaceuticals Announces Positive Results from Phase 2 Orphan Drug Designation Study of JKB-122 on Autoimmune Hepatitis (AIH) 【2019.01.22】

Source : Taiwan Healthcare+
Published : 2019-01-22

TaiwanJ Pharmaceuticals recently announced the results of phase II clinical trial of JKB-122 for the treatment of refractory Autoimmune Hepatitis (AIH) patients that demonstrated improvement on targeted objectives and relevant biomarkers from the JKB-122 treated subjects after the completion of 24-week study...

-Read More-

TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Treatment of Hemophilic Arthropathy 【2018.11.15】

Source : Taiwan Healthcare+
Published : 2018-11-15

TWi Biotechnology announced today that it has completed patient enrollment in its Phase 2 clinical trial (Study code: AC-201CR-HA-001) of AC-201CR for the treatment of hemophilic arthropathy. The Company expects to release top-line results from the interim analysis of this study in the second quarter of 2019...

-Read More-

Orient Pharma obtains Marketing Authorization for ADHD Treatment in Taiwan【2018.09.15】

Source : Taiwan Healthcare+
Published : 2018-10-15

-Read More-

Tanvex Submits BLA for Proposed Filgrastim Biosimilar【2018.10.04】

Source : Center for Biosimilars
Published : 2018-10-04

Tanvex BioPharma, a Taiwan-based biopharmaceutical company, announced this week the submission of its Biologics License Application (BLA) to the FDA for TX-01, a proposed filgrastim biosimilar referencing Neupogen...

-Read More-

Taiwan 5 Universities establish Biotech Business Incubator【2018.09.14】

Source : Taipei Times
Published : 2018-09-14

-Read More-

Japan Today: VR and AI bring New Options to Healthcare【2018.08.17】

Source : Japan Today
Published : 2018-08-17

In Japanese hospitals, virtual reality (VR) is getting real. Intuitive Surgical, the company behind the da Vinci robotic surgical system, is also exploring VR simulation training to hone physicians' robotic-assisted surgical skills. VR healthcare applications are increasingly found outside the surgical theater....

-Read More-

CellMax Life Blood Testing Platform for Early Cancer Detection Granted Six U.S. Patents【2018.08.02】

Source : Taiwan Healthcare+
Published : 2018-08-02

Patents cover entirety of sub-$200 test and platform, which isolates rare circulating tumor cells (CTCs) from one tube of blood...

-Read More-

Foresee Pharma Announces Positive Results from a Phase 1 Clinical Study of FP-045【2018.07.31】

Source : Taiwan Healthcare+
Published : 2018-07-31

Foresee Pharmaceuticals Announced on July 26 Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator….

-Read More-

US AI company to expand R&D center in Taiwan【2018.08.01】

Source : Taiwan News
Published : 2018-08-01

Graphen to expand Taiwan operations, potentially employing over one hundred more

-Read More-

Lumosa Shareholders Approved TPG Acquisition【2018.07.31】

Source : Taiwan Healthcare+
Published : 2018-07-31

-Read More-

Tanvex and Linical signed Collaboration Agreement to Expand on Japan's Biosimilar Market【2018.07.27】

Source : Taiwan Healthcare+
Published : 2018-07-27

-Read More-

Biotech firm promotes smart agriculture in Taiwan【2018.07.27】

Source : Taiwan News
Published : 2018-07-27

Taiwan's agricultural industry is ready to embrace the era of smart agriculture by using biotech resources to create value-added products...

-Read More-

Taipei Medical University leads Taiwan in Systemic Cell Therapies and Regenerative Medicine【2018.07.25】

Source : Wow News
Published : 2018-07-25

The center's work so far ranges from basic research through pre-clinical animal studies, with a triple focus on 1) stem cells and regenerative medicine, 2) use of these techniques in translational medicine, and 3) development of ethical outreach and educational services for industry and society...

-Read More-

CellMax Life's Early Cancer Detection Platform Wins 2018 MedTech Breakthrough Award【2018.07.18】

Source : Taiwan Healthcare+
Published : 2018-07-18

Leading Cancer Management Company Wins Prestigious Award for its Proprietary Circulating Tumor Cell (CTC) CMx Platform ...

-Read More-

A Taiwanese Research Team finds Mechanism of Metastasis for Breast Cancer-related【2018.07.10】

Source : Taipei Times
Published : 2018-07-10

The National Health Research Institutes (NHRI) yesterday said its researchers have discovered a mechanism that reduced the relapse and metastasis of triple negative breast cancer (TNBC) in animal testing, with future experiments to show whether it might have the same effect on the human body...

-Read More-

JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Rituximab Biosimilar【2018.07.10】

Source : JHL Biotech
Published : 2018-07-10

JHL Biotech has announced it received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the EU approval pathway for its proposed rituximab biosimilar, JHL1101.

-Read More-

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)【2018.07.09】

Source : OBI Pharma
Published : 2018-07-09

First Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme...

-Read More-

PharmaEngine Announces Positive Phase II/III Topline Results from Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma【2018.06.25】

Source : PharmaEngine
Published : 2018-06-25

PEP503 (NBTXR3) is a first-in-class product with a new mode of action physically destroying cancer cells when activated by radiation therapy. PEP503 is designed to directly destroy tumors and activate the immune system for both local control and systemic disease treatment.

-Read More-

CH Biotech Announces Grand Opening of Global R&D Innovation Center and Corporate Headquarters【2018.06.22】

Source : CH Biotech
Published : 2018-06-22

New Facility Is Taiwan's First International R&D Center Focused on Integrating Plant Health Systems...

-Read More-

Three US Scholars Awarded Tang Prize for Facilitating Targeted Cancer Therapies【2018.06.20】

Source : Taiwan Healthcare+
Published : 2018-06-20

Dr. Tony Hunter, Dr. Brian J. Druker, and Dr. John Mendelsohn are the recipients of the 2018 Tang Prize in Biopharmaceutical Science. These three renowned American scholars are awarded for the discovery of protein tyrosine phosphorylation and tyrosine kinases as oncogenes, leading to successful targeted cancer therapies...

-Read More-

JHL Biotech Announces Completion of Convertible Bond Issuance and Appointment of New CFO【2018.06.15】

Source : JHL Biotech
Published : 2018-06-15

JHL Biotech has raised US$106 million in a convertible bond issuance, which closed May 15, 2018. Proceeds raised from the issuance will be used for clinical trials, working capital needs and further development of the company's pipeline of biosimilar treatments.

-Read More-

Taiwan's NCTU, CMU Team Up to improve Cancer Treatment through Nanoparticle-based Immunotherapy【2018.06.14】

Source : Taiwan News
Published : 2018-06-14

The “fucoidan” based magnetic nanomedicine has great potential to boost immunotherapy...

-Read More-

Academia Sinica announces Newly Discovered Protein Quality Control Mechanism to Create New Opportunities in Bioengineering【2018.06.12】

Source : Academia Sinica
Published : 2018-06-12

Many human diseases such as aging, degenerative neurological diseases, and cancer are related to the defects in proteins. To remove defective proteins, cells prune themselves through a quality control mechanism that separates the wheat from the chaff.

-Read More-

A breakthrough for TFDA International pharmaceutical collaboration– Taiwan becomes the official Regulatory Member of ICH.【2018.06.12】

Source : CNA NEWS
Published : 2018-06-12

Taiwan Food and Drug Administration (TFDA) has officially become one of the ICH pharmaceutical Regulatory Member at the International Council for Harmonization (ICH) Assembly meeting at Kobe, Japan, 7th June 2018. This set a new milestone for our participations in the international pharmaceutical and technical collaborations.

-Read More-

Lumosa Therapeutics and Amed sign License Agreement for The Ten Countries of ASEAN【2018.06.09】

Source : Lumosa Therapeutics
Published : 2018-06-09

Lumosa Therapeutics Co., Ltd. announced the signing of a license agreement with Amed Co., Ltd. for its marketing and manufacture right in the ten countries of the Association of Southeast Asian Nations (ASEAN)...

-Read More-

NVIDIA and Taiwan's MOST Collaboration to Supercharge AI Efforts【2018.06.04】

Source : NVIDIA
Published : 2018-06-04

-Read More-

TLC Submits IND to US FDA Application for TLC178, Liposomal Vinorelbine Candidate for Pediatric Rhabdomyosarcoma【2018.06.04】

Source : TLC, Ltd.
Published : 2018-06-04

TLC announced the submission of an Investigational New Drug (IND) application with the U. S. Food and Drug Administration (FDA) to initiate a Phase I/II, open label, dose-escalation clinical trial of TLC178...

-Read More-

European Innovation Week kicks off in Taipei【2018.06.04】

Source : Taiwan News
Published : 2018-06-04

The largest European trade delegation in history of the event arrived in Taipei, as Taiwan's government pursues a Bilateral Investment Agreement with the EU...

-Read More-

HTC to launch DeepQ platform for AI innovations【2018.05.30】

Source : CNA NEWS
Published : 2018-05-30

In a statement, HTC said its healthcare division DeepQ will launch the DeepQ AI platform Wednesday at a graphics processing unit (GPU) technology conference, which will be held in Taipei by American integrated circuit designer NVidia.

-Read More-

Taiwan to have largest participation in Bio 2018 in Boston, MA starting June 4【2018.05.29】

Source : Taiwan News
Published : 2018-05-29

Taiwan will have the largest ever participation in the 2018 BIO International Convention that kicks off on June 4 in Boston, MA, United States, Minister Without Portfolio Wu Tsung-tsong said on Tuesday.

-Read More-

NHRI Researchers finds Three Major Factors for Liver Cancer【2018.05.22】

Source : Taipei Times
Published : 2018-05-22

The findings prove that in addition to commonly known risk factors — chronic hepatitis, alcohol addiction and cirrhosis — the three non-viral risk factors they have identified point at increased risk of developing liver cancer

-Read More-

Taiwanese Study proves that Red Sage Root help activates Fat Cells' Metabolism【2018.05.20】

Source : Taiwan News
Published : 2018-05-20

ST32da, a compound found in red sage root, is believed to turn white fat into fat-burning brown fat, according to the study

-Read More-

Applied BioCode Receives CE Mark Certification for BioCode® MDx 3000 with 18-plex Gastrointestinal Pathogen Panel【2018.05.18】

Source : Applied BioCode
Published : 2018-05-19

Applied BioCode's system will help hospitals and clinical laboratories to provide high volume syndromic testing to their patients at a more affordable cost. The GI Pathogen Panel is the first of many syndromic panels.

-Read More-

Taiwan Government designates Biotech Industry next NT$1 trillion industry【2018.05.15】

Source : CNA NEWS
Published : 2018-05-15

Taiwan's Vice President Chen Chien-jen said on May 7 that the government aims to transform the biotech industry into the next industry in Taiwan to have production value that will hit NT$1 trillion (US$33.67 billion).

-Read More-

Expanding R&D capacity into southern Taiwan, the Southern Campus of Academia Sinica officially breaks ground【2018.05.12】

Source : Academia Sinica
Published : 2018-05-12

The southern campus is to focus on the research and development of agricultural biotechnology and circular energy it will also focus on Taiwan's history and culture.

-Read More-

Collaboration between Merck and Taiwan Launched to Accelerate New Drug Manufacturing Processes in Taiwan【2018.05.10】

Source : ITRI
Published : 2018-05-10

The launch ceremony of the Biopharma R&D & Training Collaboration Program between Taiwan and Merck was held at ITRI GuangFu Innovation Campus on May 7, 2018.

-Read More-

Medigen Vaccine Biologics (MVC) ready to Market Alternative to Dengvaxia by 2022【2018.05.07】

Source : INQUIRER.net
Published : 2018-05-07

Medigen Vaccine Biologics Corp. (MVC) signed MoU with Serum Institute of India (SII). SII intends to supply MMR vaccine to alleviate Taiwan's current measles outbreak. Both parties aim to supply MMR vaccine for Taiwan's national immunization program in the future.

-Read More-

Taiwan Healthcare Companies Look At Entering India【2018.05.04】

Source : Business World
Published : 2018-05-04

With tech-aided disruption opening up in the healthcare sector, several companies from the East Asian country are looking at India. These include prominent names such as Treat You Medical Technology Corporation and Ti-Ho Healthcare Technology

-Read More-

Taiwan, France Team up to Promote Innovation Collaboration【2018.05.01】

Source : Taiwan News
Published : 2018-05-01

France will sponsor six Taiwan-based companies to visit the European country this year as part of the 'Young Enterprise Initiative'

-Read More-

Taiwanese Professor to Commercialize Tumor Detecting Technology【2018.04.28】

Source : Taiwan News
Published : 2018-04-28

The chip invented by the professor can detect a tumor within 30 minutes

-Read More-

Taiwan FDA and Malaysia NPRA signed the Collaboration Document over Pharmaceutical Regulations【2018.04.30】

Source : TFDA
Published : 2018-04-30

The signing of this collaboration document has successfully expanded exchanges and formalized the cooperation between the pharmaceutical regulatory authorities of Taiwan and Malaysia.

-Read More-

TaiMed and its partner Theratechnologies to Seek Regulatory Approval of Trogarzo™ (ibalizumab) in Europe【2018.04.25】

Source : Taiwan Healthcare+
Published : 2018-04-25

-Read More-

Medigen Vaccine Biologics Corp. and GC Pharma (GCC) Collaborate to Commercialize Quadrivalent Influenza Vaccine in Taiwan【2018.04.23】

Source : Taiwan Healthcare+
Published : 2018-04-23

-Read More-

Polaris Group advances Cancer Research with US Partner【2018.04.20】

Source : Taipei Times
Published : 2018-04-20

-Read More-

OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors【2018.04.19】

Source : Taiwan Healthcare+
Published : 2018-04-19

First clinical trial to test the safety and efficacy of a novel first-in-class targeted therapy (small-molecule prodrug) that selectively releases a potent DNA alkylating agent for solid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme

-Read More-

Compal Electronics opens Pet Hospital【2018.04.17】

Source : Nikkei Asia Review
Published : 2018-04-17

-Read More-

Acer and Taiwan's MOHW launch AI-powered Flu Forecasting Website【2018.04.12】

Source : Taiwan Today
Published : 2018-04-12

-Read More-

TLC Announces Application with U.S. FDA for Proceeding of TLC590 as Investigational New Drug (IND)【2018.04.03】

Source : Taiwan Healthcare+
Published : 2018-04-03

-Read More-

Taiwan's ‘Top 10 Coolest Technology Start-ups' focus on AI, VR and Healthcare【2018.04.03】

Source : Taipei Times
Published : 2018-04-03

-Read More-

China Medical University has Successfully Tech Transferred its 3D Printing Medical Technologies and Reaching Southbound【2018.04.02】

Source : Taiwan Healthcare+
Published : 2018-04-02

-Read More-

United Orthopedic Launches UTS™ Hip Stem and an Extension of its U-Motion II™ Acetabular System at the 2018 AAOS Annual Meeting【2018.04.01】

Source : Taiwan Healthcare+
Published : 2018-04-01

-Read More-

Taiwan's ITRI signs MoU with Biochemical Company Merck【2018.03.27】

Source : Taiwan News
Published : 2018-03-27

A new 'Taiwan-Merck Biopharma R&D and Training Collaboration Program is set to launch in May

-Read More-

InSilico Medicine announces R&D Center for Bio-medicine and AI in Taipei【2018.03.27】

Source : Taiwan News
Published : 2018-03-27

-Read More-

A Taiwan-UK Innovative Industries Program was Launched in Taipei to Improve R&D Cooperation between The Two Nations【2018.03.26】

Source : Taipei Times
Published : 2018-03-26

-Read More-

New Light for the Treatment of Glioblastoma Multiforme, Everfront Biotech Launch Clinical Trial【2018.03.23】

Source : Taiwan Healthcare+
Published : 2018-03-23

Hualien Tzu Chi Hospital had completed “the Phase I study of Human Pharmacology on GBM patient who relapsed.” He received target drugs implantation into intracerebral on December 25th, 2017.

-Read More-

Premier Lai: Taiwan to Become a Global Hub for Biomedical Industry【2018.03.19】

Source : Taipei Times
Published : 2018-03-19

The government is leaving no stone unturned in promoting Taiwan's biomedical industry and transforming the nation into a global R&D hub for medical devices and pharmaceuticals.

-Read More-

Wistron Medical and NTU Hospital Collaborate on Medical Rehabilitation Robot【2018.03.09】

Source : CTIMES
Published : 2018-03-09

-Read More-

US FDA approves TaiMed's HIV Drug, Stock soars 10%【2018.03.08】

Source : Taipei Times
Published : 2018-03-08

In a study of 40 people who no longer respond to other antiretroviral treatments, 43 percent achieved HIV RNA suppression, the FDA said

-Read More-

Adimmune says Flu Vaccine to Drive Business【2018.03.07】

Source : Taipei Times
Published : 2018-03-07

-Read More-

Taiwan's Agriculture Minister: Agricultural Technology Transfer to Benefit Both of Malaysia and Taiwan 【2018.03.05】

Source : BUSINESS WIRE
Published : 2018-03-05

Taiwan hopes, in collaboration with new southbound countries, to promote the regional development of agriculture by improving bilateral cooperation in information, technology and talents to secure the sustainable agriculture

-Read More-

TLC targets fast US FDA approval【2018.02.24】

Source : Taipei Time
Published : 2018-02-24

-Read More-

US Patent Granted for Lumosa's New Drug to Treat Acute Ischemic Stroke【2018.02.22】

Source : Lumosa
Published : 2018-02-22

-Read More-

Taiwan's Foreign Professional Talent Act goes into Effect【2018.02.12】

Source : Taiwan News
Published : 2018-02-12

Act for the Recruitment and Employment of Foreign Professional Talent takes effect

-Read More-

Taiwan Passes Patent Linkage Legislation【2018.02.12】

Source : Taiwan Business TOPICS
Published : 2018-02-12

Taiwan's patent linkage system provides notice of a patent owner's rights to potential competitors. In the United States, this concept is most often associated with the Drug Price Competition and Patent Term Restoration Act, otherwise known as the Hatch-Waxman Act. The patent linkage systems in Taiwan appear to be inspired by the Hatch-Waxman Act.

-Read More-

Foxconn to Invest USD 340 mln for AI and Healthcare Solutions【2018.02.06】

Source : CNA NEWS
Published : 2018-02-06

Hon Hai said it aims to develop healthcare solutions based on big data-driven technologies, and Internet-based security solutions for other sectors

-Read More-

ACT Genomics, AstraZeneca enter Collaboration for BRCA Testing in Singapore and Taiwan【2018.02.06】

Source : ACT Genomics
Published : 2018-02-06

ACT Genomics is honoured to collaborate with AstraZeneca Singapore for both somatic and germline genetic testing of BRCA in patients with ovarian cancer, using the advanced next generation sequencing (NGS) technology.

-Read More-

Taiwan Medical Companies Showcase ‘Smart' Surgical Machines【2018.02.06】

Source : Taipei Times
Published : 2018-02-06

The Retina system allows a surgeon to peer into a patient's skull using augmented reality goggles, boosting precision and efficiency

-Read More-

Sinphar Earnings Stability to Support its R&D in Pancreatic Cancer Drug【2018.01.30】

Source : Taipei Times
Published : 2018-01-30

Sinphar Group can generate ample profit to fund SynCore's phase III trials, which is expected to cost about NT$1 billion (US$33.98 million)

-Read More-

CellMax Life's New CTC Test detects Early Stage Colorectal Cancer and Pre-cancer with High Accuracy【2018.01.29】

Source : Healthcare Global
Published : 2018-01-29

The new blood test showed a high degree of accuracy for detecting early-stage colorectal cancer — accuracy ranged from 84% to 89% — and it is the first assay to demonstrate high sensitivity in the detection of precancerous colorectal lesions.

-Read More-

TLC and Jixi Biotechnology Partners Announce Joint Venture【2018.01.23】

Source : TLC
Published : 2018-01-23

-Read More-

Lumosa Therapeutics Licenses Long Acting Injectable Analgesic to Skyline Vet Pharma, Inc. for Use in Companion Animals【2018.01.17】

Source : Lumosa Therapeutics
Published : 2018-01-17

Licensing agreement brings Taiwan-developed pet medicine to US, Canada, NZ, and Australia.

-Read More-

Taiwan Biomedical Revenues may Break NT$500 Billion in 2018【2018.01.10】

Source : DigiTimes
Published : 2018-01-10

The annual revenues of Taiwan's biomedical industry are estimated to rise 4.5% on year to reach NT$488.4 billion (US$16.54 billion) in 2017 and are likely to break the NT$500 billion level in 2018, bolstered by concerted efforts by the government and private sectors, according to statistics released by Taiwan's Ministry of Science and Technology (MOST).

-Read More-

Foresee Pharma enters into license and distribution agreement with Megapharm【2018.01.06】

Source : Pharma Journalist
Published : 2018-01-06

Foresee Pharmaceuticals and Megapharm Announce License and Distribution Agreement. They have entered into an exclusive license and distribution agreement for the commercialisation in Israel and the Palestinian Authority of Foresee's FP-001 program, LMIS (Leuprolide Mesylate Injectable Suspension) ready-to-use subcutaneous depot formulations.

-Read More-

PwC Forecasts Increase in Taiwan Biotech IPO Activity This Year【2018.01.05】

Source : Taipei Times
Published : 2018-01-05

Local initial public offering (IPO) activity could pick up significantly this year as firms that delayed an application last year take action, encouraged by rallies of the local bourses, PricewaterhouseCoopers Taiwan (PwC) said.

-Read More-

ASLAN Pharmaceuticals Gets Global Rights to Develop Tumor Drug【2018.01.04】

Source : Taipei Times
Published : 2018-01-04

ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for Varlitinib from Array BioPharma for Up to $129M...

-Read More-

Taiwan Scientists find Key in Pluripotent Stem Cells【2018.01.03】

Source : Xinhua Net
Published : 2018-01-03

Taiwanese scientists have discovered that circular RNA (circRNA) plays a key functional role in pluripotent stem cells, which may help the development of regenerative medicine or medical technologies.

-Read More-

An International Team creates More Efficient Conversion Method for Biomass【2018.01.03】

Source : Taipei Times
Published : 2018-01-03

An international team of researchers from Taiwan, Australia, India and Bangladesh has successfully developed a method of converting agricultural biomass into commercially valuable chemicals for food and pharmaceutical companies, according to a report in the Financial Express.

-Read More-

PharmaEngine announces its partner, Nanobiotix, received an IND approval from US FDA to conduct a Phase I&II trial of PEP503（NBTXR3）with anti-PD-1 antibodies【2018.01.01】

Source : PharmaEngine
Published : 2018-01-01

PharmaEngine, Inc. announced that its partner, Nanobiotix (Euronext: NANO), has been granted an Investigational New Drug (IND) approval by the U.S. Food and Drug Administration (FDA) for PEP503 (NBTXR3) activated by radiotherapy, and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).

-Read More-

JHL Biotech Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis【2018.01.01】

Source : JHL Biotech
Published : 2018-01-01

JHL Biotech Inc. announced last week that it has submitted a Phase 1 Clinical Trial Application to the Dutch Healthcare Authority for its proposed dornase alfa biosimilar, JHL1922, to improve pulmonary function of cystic fibrosis patients.

-Read More-

PharmaEssentia expects EU Marketing Approval【2017.12.20】

Source : Taipei Times
Published : 2017-12-20

PharmaEssentia Corp yesterday said it expects to gain marketing approval in Europe before the end of the third quarter next year for its new P1101 polycythemia vera (PV) drug.The company is also seeking approval from US authorities for the drug.

-Read More-

EirGenix to Begin Global Trial for A Copy of Its Cancer Drug【2017.12.18】

Source : EirGenix
Published : 2017-12-18

PHASE III: As the trial is expected to cost between 50 million and 80 million euros, the company is in talks with five potential strategic partners to share the expense

-Read More-

Asus Life Rolls out New Smart Robot for Medical Use at the Taiwan Healthcare+ Expo【2017.12.18】

Source : Taipei Times
Published : 2017-12-18

ASUS Life aims digital medical treatments through strategic alliance with Clinerion

-Read More-

TaiGen's Taigexyn Received Reimbursement Price from Taiwan's National Health Insurance Administration 【2017.12.18】

Source : TaiGen Biotechnology
Published : 2017-12-18

TaiGen announced on Dec. 7 that it has been officially notified by Taiwan's National Health Insurance Administration (NHI) of the reimbursement price for Taigexyn® (Nemonoxacin) 250 mg capsules.

-Read More-

TaiGen : Russian Partner Has Completed Enrollment for the Phase III Clinical Trial of Taigexyn【2017.12.05】

Source : Taiwan Healthcare+
Published : 2017-12-05

TaiGen announced that its Russian partner, R-Pharm JSC, has completed the patient enrollment of the Phase 3 clinical trial of Taigexyn® (nemonoxacin) in Russia. After the study is complete (last patient last visit), the results will be unblinded, analyzed and compiled into a new drug application (NDA) for filing in 2018.

-Read More-

Huijia Health Life Technology Wins 2017 R&D 100 Award Showcasing Taiwan's Smart Medical Research and Development Capability【2017.11.30】

Source : Taiwan Healthcare+
Published : 2017-11-30

Huijia Health Life Technology announced that it has won the 55th R&D 100 Award in Orlando, USA on November 17. It shows that the fiber optic physiological monitoring technology of Huijia Health has a significant impact on human life and is internationally recognized.

-Read More-

GeneReach's In Vitro Diagnostic Product for the Detection of Dengue Virus has Begun Exported to Panama【2017.11.28】

Source : Taipei Times
Published : 2017-11-28

EXPANDING ITS MARKET: The company is working to broaden its scope. It said its dengue IVD diagnostic product is being reviewed by regulators in Taiwan and Southeast Asia.

-Read More-

Taiwan Passes Law on Hiring Professional Foreign Talent Last Month【2017.11.28】

Source : Taiwan Healthcare+
Published : 2017-11-28

The Act Governing Recruitment and Employment of Foreign Professionals extends work and residence permits for foreign white-collar professionals from the current maximum of three years to five.

-Read More-

TaiGen's Intravenous Taigexyn® Successfully Completed Phase 3 Clinical Trial for Community Acquired Pneumonia in Taiwan【2017.11.27】

Source : TaiGen Biotechnology
Published : 2017-11-27

TaiGen announced on Nov 6 that it has completed the Phase 3 clinical trial of the intravenous formulation of Taigexyn® (Nemonoxacin) in Taiwan.

-Read More-

Taiwan Generics Maker TWi adds Ophthalmic Asset【2017.11.21】

Source : TWi Pharma
Published : 2017-11-21

Taipei-based generics maker TWi Pharmaceuticals has bought Synpac-Kingdom Pharmaceutical (SKP), another generics supplier known for ophthalmic treatments, for NT$1.8 billion ($59.8 million). The deal is expected to be completed by the end of this year.

-Read More-

Sinphar Inked a Technology Transfer Agreement with A Major Japanese Eye Medication Supplier【2017.11.20】

Source : Sinphar Pharma
Published : 2017-11-20

-Read More-

TaiMed Biologics Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018【2017.11.20】

Source : TaiMed Biologics
Published : 2017-11-20

the U.S. FDA will extend its review of the BLA for Ibalizumab. In a notice received today by TaiMed from the FDA, the Prescription Drug User Fee Act ("PDUFA") target action date has been extended to April 3, 2018.

-Read More-

Five Ways Asian Countries are Pushing Ahead in Health Technology【2017.11.15】

Source : Financial Post
Published : 2017-11-15

Asia's health-care innovations are in the early stages and have the backing of governments keen to build cutting-edge medical technologies

-Read More-

Taiwan Government Hopes to Reduce Unnecessary Healthcare Expenditure by Introduce More Information Technology【2017.11.14】

Source : Taipei Times
Published : 2017-11-14

EXPENSIVE TREATMENT:The premier said cancer medication cost the nation NT$32.2 billion last year, about 38 percent of treatment costs, and he hoped to bring this down

-Read More-

TWi's ANDA of Bupropion HCI ER Tablet has been Approved by US FDA【2017.11.13】

Source : Twi Pharma
Published : 2017-11-13

TWi Pharmaceuticals, Inc. (“TWi”) last week announced that its ANDA (“Abbreviated New Drug Application”) of Bupropion HCl ER Tablet (TWi-015) has been officially approved by US FDA.

-Read More-

Breast Cancer Cells Empowered in Tumor-draining Lymph Nodes by Tregs【2017.11.07】

Source : Academia Sinica
Published : 2017-11-07

When breast cancer cells are found in the lymph nodes, it is considered an important prognostic predictor for patient survival. However, whether tumor-draining lymph nodes (TDLNs) take parts in the course of breast cancer metastasis has never been thoroughly looked at.

-Read More-

Taiwan Shines at iENA Nuremburg Invention Fair【2017.11.06】

Source : Central News Agency
Published : 2017-11-06

Taiwan won a total of 36 medals out of more than 800 submissions from across the world at this year's iENA International Trade Fair Ideas - Inventions - New Products held in Nuremburg, Germany from Nov. 2-5.

-Read More-

Lotus Pharma Court Challenge in US over Generic Drug【2017.11.06】

Source : Taipei Times
Published : 2017-11-06

Lotus Pharmaceuticals Co on Tuesday said it has successfully challenged a patent claim that has been blocking the company's efforts to commercialize a generic drug.

-Read More-

Shanghai Fosun Pharma to Buy Stake in Taiwan's Henlix Biotech for Up to $98 mln【2017.11.03】

Source : Nikkei Asia Review
Published : 2017-11-03

Shanghai Fosun Pharmaceutical (Group), a company controlled by Chinese conglomerate Fosun International, said a unit has agreed to acquire the 69.25% stake it doesn't already own in Taiwan-based biopharmaceutical company Henlix Biotech for up to $98 million.

-Read More-

OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics【2017.10.30】

Source : OBI Pharma
Published : 2017-10-30

Study finds OBI-3424 exerts profound in vivo efficacy and safety against patient-derived xenograft (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL) expressing AKR1C3.

-Read More-

Tanvex Biopharma is publicly traded on Taiwan Stock Exchange since Oct. 26【2017.10.30】

Source : Taiwan Healthcare+
Published : 2017-10-30

Just last month Tanvex BioPharma announced its plans for an international Phase 3 trial of its biosimilar drug candidate, TX05, its investigational trastuzumab biosimilar (a proposed biosimilar to Herceptin®) in patients with early stage breast cancer.

-Read More-

The Global Health Forum in Taiwan, Drawing an International Crowd【2017.10.23】

Source : Taipei Times
Published : 2017-10-23

The Global Health Forum in Taiwan, organized by the Ministry of Health and Welfare and the Ministry of Foreign Affairs, opened in Taipei yesterday, attracting 58 experts from 35 nations and hundreds of participants.

-Read More-

Herbal Remedies Linked to Cases of Liver Cancer across Asia【2017.10.23】

Source : The Japan Times
Published : 2017-10-23

Taiwan and Singapore's researchers have uncovered widespread evidence of a link between traditional Chinese herbal remedies and liver cancer across Asia, a study said last Wednesday.

-Read More-

EirGenix Plant on Schedule, Annual Production Capacity of More Than 1,000kg【2017.10.23】

Source : Taipei Times
Published : 2017-10-23

EirGenix Inc in the last week said construction of its new large-scale protein production plant is on schedule and it is expected to go online in the final quarter of next year.

-Read More-

Taiwan FDA: Heading Southward!【2017.10.21】

Source : TFDA
Published : 2017-10-21

At present, all pharmaceutical manufacturers in Taiwan have fully complied with PIC/S GMP standards and most of the medical devices meeting the criteria of the EU and the US.

-Read More-

TLC Showcases Superiorities at Janney's Osteoarthritis & Pain Therapeutic Forum【2017.10.17】

Source : TLC, Ltd.
Published : 2017-10-17

At Janney's Osteoarthritis and Pain Therapeutic Forum, TLC showcased its solutions to pain management and demonstrated superiorities in its data against peers during the 30-minute presentation.

-Read More-

Foreign Firms Plan US$3.5bn Investment Taiwan 【2017.10.17】

Source : Taipei Times
Published : 2017-10-17

The Ministry of Economic Affairs and 22 foreign companies signed letters of intent at a Taiwan Business Alliance conference in Taipei, with the companies pledging investments of NT$106.3 billion (US$3.5 billion) over three years.

-Read More-

Taiwan Government Approves Four-year Science and Technology Development Program to Boost AI and Digital Technologies【2017.10.03】

Source : Taipei Times
Published : 2017-10-03

The Taiwan government last Friday approved a four-year science and technology development program to boost the digital economy and to use “smart” technologies to meet various challenges facing the nation, such as an aging population and climate change.

-Read More-

CHO Pharma Hopes to Become the TSMC of the Biotech Field, Trading Yesterday During Its Debut on the TPEX【2017.09.28】

Source : Taipei Times
Published : 2017-09-28

In the field: A broad-spectrum cancer antibody, based on the findings of a former Academia Sinica president, kills cancer cells by targeting novel carbohydrate antigens.

-Read More-

Foresee Pharma and TRPharm Announce License and Distribution Agreement【2017.09.28】

Source : Foresee Pharma
Published : 2017-09-28

Foresee Pharma And TRPharm announced yesterday that they have entered into an exclusive license and distribution agreement for the commercialisation in Turkey and certain Middle East countries of Foresee's FP-001 program.

-Read More-

Hereditary and Environmental Factors are Just as Critical as Smoking in Causing Cancer: Taiwan Study【2017.09.25】

Source : Taipei Times
Published : 2017-09-25

The study confirms that hereditary and environmental factors are just as critical as smoking in causing cancer, said Yang Pan-chyr, who led the research.

-Read More-

Taiwan and India Eager to Join Hands on Healthcare【2017.09.25】

Source : Taiwan News
Published : 2017-09-25

Taiwanese delegation visits India's Ministry of Health and Family Welfare

-Read More-

NCKU Research Team cracks The Mysterious Origins of Orchids: Taiwan Study【2017.09.21】

Source : CNA NEWS
Published : 2017-09-21

A research team at National Cheng Kung University (NCKU) has cracked the code on the evolution of orchids, the school in southern Taiwan said Thursday.

-Read More-

Tang Prize Winner:Taiwan should Invest in Basic Research and Translational Research【2017.09.16】

Source : Taipei Times
Published : 2017-09-16

Chinese-American biologist and Tang Prize winner Zhang Feng said that Taiwan should invest in basic research and translational research to help establish itself in the global biotechnology sector.

-Read More-

2017 PIC/S Committee Meeting and Seminar Conclude Successfully in Taiwan with Spectacular Results【2017.09.15】

Source : TFDA
Published : 2017-09-15

The 2017 PIC/S Committee Meeting and Seminar took place in Taiwan, bringing together 170 official inspectors representing 60 regulatory authorities and three international organization from 50 countries, including the U.S., Canada, the U.K., Germany, Switzerland, France, Italy, the Netherlands, Denmark, Belgium, Sweden, Japan, South Korea, Singapore, Malaysia, Indonesia, Thailand, New Zealand, Australia, South Africa and etc.,. Inspectors worldwide are gathering in Taipei to discuss the GMP regu

-Read More-

Global Inspectors Gathering in Taiwan to Harmonize The GMP Regulation in The Field of Medicinal Products【2017.09.11】

Source : TFDA
Published : 2017-09-11

The 2017 PIC/S Committee Meeting and Seminar, the biggest annual event of PIC/S, take place from September 11th to 15th in Taipei. Nearly 175 GMP inspectors representing 62 regulatory authorities from 52 countries.

-Read More-

Taiwan Government to Fund 30,000 Tech Start-ups in Three Years【2017.09.08】

Source : Electronics Weekly.Com
Published : 2017-09-12

Taiwan aims to create 30,000 tech start-ups in the next three years, reports Digitimes.

-Read More-

Taiwan Proposes New Rules on Health Supplements【2017.09.07】

Source : out-law.com
Published : 2017-09-07

Health supplements sold in Taiwan will have to clearly state that they are "non-medicine" and have "no curative effect" under new regulations proposed this week, China News has reported.

-Read More-

TPG Capital Asia Buys Majority Stake In Taiwan-Based Clinical Trials Firm OPC【2017.09.04】

Source : China money network
Published : 2017-09-04

TPG Capital Asia has acquired a majority stake in Taiwan-based clinical trial services provider OPC Holding Company. As part of the transaction, OPC's founder Jason Chen will transition to the role of chairman. Additional terms of the transaction were not disclosed.

-Read More-

Foxconn Planned Investment in The Czech will be Aimed Medical Care Products【2017.08.30】

Source : CNA NEWS
Published : 2017-08-30

Taiwan-based manufacturing giant Foxconn Technology Group is planning to boost its investment in Czech Republic, according to the country's English-language Prague Daily Monitor.

-Read More-

Scientist Expects Biomed Research to Remain Focused on Antibodies【2017.08.29】

Source : CNA NEWS
Published : 2017-08-29

Antibody and small molecule drugs and big data applications will remain at the center of biomedical research in the future, according to Andrew Wang, president-elect of the International Union of Biochemistry and Molecular Biology (IUBMB).

-Read More-

Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain in the US【2017.08.28】

Source : Lumosa Therapeutics
Published : 2017-08-28

Naldebain® IM injection has received market authorization and launched in Taiwan as the world's first 7-day long-acting analgesic injection for moderate to severe post-operative pain.

-Read More-

ASLAN Pharmaceuticals announces New Research Collaboration with Academia Sinica's Genomic Research Centre in Taiwan【2017.08.22】

Source : Aslan Pharma
Published : 2017-08-22

A research collaboration joins Aslan with an academic research institute for studying small-molecule cancer drug candidates.

-Read More-

Taiwan Biotech and Medical Fund Expected to Complete Fundraising by The End of The Year【2017.08.16】

Source : Taipei Times
Published : 2017-08-16

Line Corp is considering investing in a planned government-backed investment firm supervised by the National Development Council (NDC), council Deputy Minister Kung Ming-hsin said on last Thursday (10 Aug).

-Read More-

TaiMed Biologics's Manufacturing Partner Completed Pre-License Inspection for Production of TMB-355 (ibalizumab)【2017.08.14】

Source : TaiMed Biologics
Published : 2017-08-14

-Read More-

Orient Pharma Announce Positive Results from Phase 3 Clinical Study of ORADURR-Methylphenidate (2PN012) for ADHD【2017.08.10】

Source : Orient Pharma
Published : 2017-08-10

-Statistically significant difference between ORADURR-Methylphenidate (2PN012) and placebo on SNAP-IV teacher form score - Study drug was generally safe and well tolerated

-Read More-

Formosa Pharma, A Wholly-owned Subsidiary of Formosa Labs, Acquires Activus Pharma, A Subsidiary of Sosei Group【2017.08.08】

Source : Formosalab
Published : 2017-08-08

Formosa Laboratories, Inc. (Formosalab) is pleased to announce that the company has entered into an agreement under which it will make an investment in and acquire Activus Pharma, (hereafter, Activus), a wholly-owned subsidiary of Sosei Group Corporation (Sosei).

-Read More-

ScinoPharm to Provide Contract Manufacturing Service for Melinta 's Newly-Approved Serious Skin Infections Drug, Baxdela™【2017.08.04】

Source : ScinoPharm
Published : 2017-08-07

-Read More-

First Human Subject Enrolled in Lumosa Therapeutics' Phase 1 Trial for LT3001, a New Drug Molecule for Acute Ischemic Stroke【2017.08.01】

Source : Lumosa Therapeutics
Published : 2017-08-01

-Read More-

Foresee Pharmaceuticals Announces CEO Appointment【2017.08.01】

Source : Foresee Pharma
Published : 2017-08-01

-Read More-

TLC Receives Orphan Drug Designation by US FDA of TLC178 for the Treatment of Soft Tissue Sarcoma【2017.07.24】

Source : TLC, Ltd.
Published : 2017-07-24

-Read More-

Foresee Pharmaceuticals Announces US FDA IND Approval for Initiation of Phase 3 trial of LMIS 25 mg【2017.07.24】

Source : Foresee Pharm
Published : 2017-07-24

Foresee announced the approval of an IND application by the US FDA for LMIS 25 mg. LMIS 25 mg is a line-extension product of FP-001, LMIS 50 mg, a 6-month, ready-to-use subcutaneous depot formulation.

-Read More-

SynCore Biotechnology Receives IND Clearance of SB05 (EndoTAG®-1) by the TFDA to Conduct a Phase III Clinical Trial for the Treatment of Metastatic Adenocarcinoma of the Pancreas【2017.07.21】

Source : SynCore
Published : 2017-07-21

Investigational New Drug (IND) clearance from TFDA represents a key milestone in SynCore's new drug pipeline development program. The global Phase III study has Orphan Drug Designation granted by US FDA and European Medicines Agency for the indication of metastatic Pancreatic Cancer. Commercial opportunity launch for a preferential product against an unmet medical need as first and only therapy of its kind with a strong intellectual property position.

-Read More-

TSH Biopharm, Mycenax Biotech biosimilar version of Enbrel®(etanecept) wins Taiwan FDA approval【2017.07.18】

Source : Taiwan Healthcare+
Published : 2017-07-18

TuNEX：The first self-developed biosimilar by the local biotech companies approved in Taiwan

-Read More-

TLC Announces Issuance of Patents for Three Product Candidates【2017.07.18】

Source : TLC, Ltd.
Published : 2017-07-18

-Read More-

Abzena and OBI Pharma Sign ThioBridge™ Licence Agreement【2017.07.11】

Source : Abzena
Published : 2017-07-11

Master Services and Clinical Supply agreement to enable process development and manufacturing by Abzena.

-Read More-

Taiwan joins forces with Insilico Medicine to apply AI to biomedical research【2017.07.05】

Source : DCB, PITDC, TMU
Published : 2017-07-05

The Development Center for Biotechnology (DCB), the Medical and Pharmaceutical Industrial Technology Development Center (PITDC), and Taipei Medical University (TMU), three of Taiwan's premier biomedical institutions, have teamed up with Baltimore-based Insilico Medicine to develop groundbreaking research in applied A.I. for biomedical science. The four parties signed a Letter of Intent (LoI) for Cooperation at the BioTaiwan 2017 BioBusiness Asia Conference.

-Read More-

PharmaEssentia renegotiates terms for its new orphan drug【2017.07.05】

Source : Taipei Times
Published : 2017-07-05

PharmaEssentia might receive as much as 20 percent of sales of P1101, its polycythemia vera drug, up from 16 percent of sales under a previous agreement

-Read More-

Taiwan government to set up national investment firm【2017.07.04】

Source : Taipei Times
Published : 2017-07-04

ECONOMIC DRIVER:The company, which will run three funds, is to be under the remit of the National Development Council and be capitalized at NT$250m

-Read More-

SynCore positive on goals for pancreatic cancer drug【2017.06.30】

Source : Taipei Times
Published : 2017-06-30

-Read More-

AOP and PharmaEssentia present positive results from 3 studies of Ropeginterferon alfa-2b in patients with PV at EHA meeting【2017.06.27】

Source : Pharmabiz
Published : 2017-06-27

-Read More-

USFDA accepts Lumosa Therapeutics's phase 1 trial for LT3001【2017.06.20】

Source : Lumosa Therapeutics
Published : 2017-06-20

Lumosa Therapeutics Co., Ltd. is pleased to announce that its lead drug candidate for acute ischemic stroke, LT3001, has received approval from the US FDA to begin Phase I clinical trials. The first clinical trial is a double-blinded dose escalating study in healthy volunteers and expected to be completed in the first half of 2018.

-Read More-

Taiwan scientists find potential treatment for Alzheimer's disease【2017.06.17】

Source : CNA News
Published : 2017-06-17

-Read More-

Exploring Biotech Business Opportunities in Indonesia.【2017.06.02】

Source : Taiwan Healthcare+
Published : 2017-06-02

Taiwan Healthcare+ led 6 THP companies to TAIWAN EXPO 2017 di Indonesia in Jakarta Convention Center from May 12 to 14 to promote business with local partners. The exhibition brought in a total of 73 potential business partners for the THP alliance companies.

-Read More-

TLC Submits Marketing Authorization Application in Europe for TLC177【2017.05.23】

Source : TLC, Ltd.
Published : 2017-05-23

-Read More-

SynCore Bio to Present the Phase I Study of SB01 at ASCO 2017【2017.05.23】

Source : SynCore Biotech
Published : 2017-05-23

-Read More-

SciVision Biotech Published its Trial Results of Single Intra-articular Injection of Novel Hyaluronan (HYA-JOINT Plus) in The Journal of Bone & Joint Surgery (JBJS)【2017.05.18】

Source : SciVision biotech
Published : 2017-05-18

Comparison of Single Intra-Articular Injection of Novel Hyaluronan (HYA-JOINT Plus) with Synvisc-One for Knee Osteoarthritis: A Randomized, Controlled, Double-Blind Trial of Efficacy and Safety

-Read More-

Amcad-UV has Won FDA Approval, Solidifying Amcad's Position in High-end Medical Imaging Device Market【2017.05.09】

Source : AmCad BioMed
Published : 2017-05-09

-Read More-

TLC178 Designated by US FDA as Drug for Rare Pediatric Disease in the Treatment of Rhabdomyosarcoma【2017.05.04】

Source : TLC, Ltd.
Published : 2017-05-04

-Read More-

US FDA Allows SynCore Biotechnology to Run a Phase III Clinical Trial in Metastatic Adenocarcinoma of the Pancreas【2017.04.24】

Source : SynCore Biotech
Published : 2017-04-24

-Read More-

Top five innovative Taiwan advanced medical imaging devices【2017.04.14】

Source : Taiwan News
Published : 2017-04-14

-Read More-

Taiwan's EpiSonica solves dense breast imaging issues with painless smart scanning device【2017.04.14】

Source : Taiwan News
Published : 2017-04-14

-Read More-

Taiwan to invest NT$2 billion in medical equipment industry by 2020【2017.04.13】

Source : Taiwan News
Published : 2017-04-13

Taiwan's Economic Ministry to invest NT$ 2 billion to develop domestic medical equipment industry

-Read More-

PharmaEssentia's European partner AOP Orphan announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera 【2017.03.31】

Source : AOP Orphan Pharmaceuticals AG
Published : 2017-03-31

-Read More-

TaiGen Biotechnology and HEC Pharmaceutical Executed Equity Purchase Agreement for Their HCV Joint Venture 【2017.03.28】

Source : TaiGen Biotechnology
Published : 2017-03-28

-Read More-

Lumosa Therapeutics gets TFDA approval for its long-acting analgesic injection named NALDEBAIN,LT1001【2017.03.20】

Source : Lumosa Therapeutics
Published : 2017-03-20

LT1001：World's First 7-Day Long-Acting Analgesic Injection

-Read More-

Two Approvals Granted by TFDA, SciVision Biotech Net Profit Hits Higher【2017.03.10】

Source : SciVision Biotech
Published : 2017-03-10

SciVision Biotech has two approvals of "hyaluronic acid-based adhesion" and "Intravesical Instillation", which makes their net profit hits higher

-Read More-

United Orthopedic to Acquire A-Spine Asia for about $20 Million US Dollars【2017.03.09】

Source : United Orthopedic Corporation
Published : 2017-03-09

United Orthopedic Corporation is capable of in house R&D, manufacture and sales of high-tech medical device. United has been selling its products to more than thirty countries and the Gross Margin reached 70%.

-Read More-

Baxter and ScinoPharm Announce Exclusive Strategic Partnership for Generic Oncology Injectables【2017.03.02】

Source : ScinoPharm Taiwan, Ltd
Published : 2017-03-02

• Arrangement includes five generic injectables used in cancer treatment, with option to add up to 15 more molecules • Collaboration combines ScinoPharm's world-class API expertise with Baxter's differentiated capabilities in difficult-to-manufacture oncology drugs and extensive global presence in hospital channel • Partnership augments Baxter's growing generic injectables business with high-quality essential medicines that will benefit patients worldwide

-Read More-

Panion & BF Biotech Inc. (PBF) announces License and Exclusive Distribution Agreement with KKKR【2017.02.24】

Source : Edward Ting, Spokesman of PBF Biotech Inc.
Published : 2017-02-24

PBF and KKKR have entered license and exclusive distribution agreement for market authorization application and the following commercialization of "Nephoxil®" in Korea

-Read More-

TLC Collaborates with CMUH in Exploring Solutions for Unmet Medical Needs in Oncology & Osteoarthritis【2017.02.23】

Source : Taiwan Liposome Company, Ltd.
Published : 2017-02-23

TLC and CMUH signed an agreement to collaborate in the execution of clinical trial programs for drugs developed by TLC to address unmet medical needs. The clinical trials of these drugs are all multi-center trials. In addition to sites in Taiwan, trials will concurrently recruit patients from China, Australia and the U.S.

-Read More-

ScinoPharm Reports Financial Performance for 2016【2017.02.17】

Source : ScinoPharm Taiwan, Ltd
Published : 2017-02-17

In 2016, overall revenue increased by 2% compared to 2015 primarily as a result of the sales boost of generic APIs, including an increased market share of Gemcitabine combined with more flexible strategies, increased shipments of Paclitaxel, as well as greater customer needs of Entecavir (HBV) and Riluzole (ALS) in anticipation for commercial launch.

-Read More-

Orient Pharma's famed cholesterol-lowering drug approved for listing in the United States【2017.02.15】

Source : Taiwan Healthcare+
Published : 2017-02-15

Orient Pharma Co., Ltd announced on February 6 that its new drug application (NDA) for its cholesterol-lowering generic drug, Pitavastatin, has been approved by the United States FDA.

-Read More-

Adimmune Corporation begins shipments to EU【2017.02.10】

Source : Adimmune Corporation
Published : 2017-02-10

The demand for Enoxaparin Sodium is strong in Europe and Adimmune expects the utilization rate of its PFS production line to ramp up quickly after mass production, boosting 2017 top-line growth.

-Read More-

Cross Strait Recognition for Clinical Trials Conducted by Four Hospitals on Both Sides【2016.10.11】

Source : Taiwan Today
Published : 2016-10-11

Taiwan and mainland China recently recognized for the clinical drug tests conducted by four hospitals on both sides. This breakthrough eliminates the need to conduct another set of clinical trials in mainland China, cutting considerable time off the approval process for drug-makers developing new products.

-Read More-

TaiMed Biologics' Ibalizumab (TMB-355) was chosen Top 40 drugs in 2016 by Chemical & Engineering News【2016.09.04】

Source : C&EN
Published : 2016-09-04

TaiMed's Ibalizumab is the only drug be chosen for curing HIV. TaiMed and Theratechnologies announced a successful outcome for a single-arm Phase III trial in which 33 out of 40 patients, and completed enrollment for a second Phase III trial.

-Read More-

Taiwan's iStat Biomedical Gets CE Mark for HPV-Associated Cancer Products【2016.08.29】

Source : GenomeWeb
Published : 2016-08-29

iStat Biomedical has successfully gained CE approval of five IVD (DNA Methylation and related) products from the European Authority These products concordance with the gold-standard cytological evaluations or HPV typing, are expected to reduce some of the interventional procedures unnecessarily performed and alleviate anxiety due to diagnostic uncertainties.

-Read More-

ONIVYDE of PharmaEngine Being Granted By CHMP for Treatment of Metastatic Pancreatic Cancer【2016.07.25】

Source : PharmaEngine, Inc.
Published : 2016-07-25

-Read More-

People who like this also like

China Medical University has Successfully Tech Transferred its 3D Printing Medical Technologies and Reaching Southbound【2018.04.02】
Amcad-UV has Won FDA Approval, Solidifying Amcad's Position in High-end Medical Imaging Device Market【2017.05.09】
ApexCare integrated Design Thinking Into Agile Development to Provide Safer and Better Quality Long-Term Care Equipment for its Clients
Taiwan Shines at iENA Nuremburg Invention Fair【2017.11.06】
Opportunities and Challenges in Investing in Taiwan's Biomedical Industry
NCKU Research Team cracks The Mysterious Origins of Orchids: Taiwan Study【2017.09.21】
CH Biotech Announces Grand Opening of Global R&D Innovation Center and Corporate Headquarters【2018.06.22】
Two Approvals Granted by TFDA, SciVision Biotech Net Profit Hits Higher【2017.03.10】
Taiwan Regulatory Framework for Medicinal Products has been Accredited by The PIC/S: TFDA
Baxter and ScinoPharm Announce Exclusive Strategic Partnership for Generic Oncology Injectables【2017.03.02】

TEL：	886-2-26558168	FAX：	886-2-26557978	Email：	thp@ibmi.org.tw
Address：16F.-1, No.3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)

TEL：	886-2-26558168	FAX：	886-2-26557978
Address：16F.-1, No.3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)

Copyright ©		Institute for Biotechnology and Medicine Industry,
		Research Center for Biotechnology and Medicine Policy. All rights reserved.